Severe acute respiratory syndrome coronavirus 2 vaccination in children with a history of multisystem inflammatory syndrome in children: an international survey

The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not...

Descripción completa

Detalles Bibliográficos
Autores: Hoste, Levi, Soriano-Arandes, Antoni, Buddingh, Emilie Pauline, Whittaker, Elizabeth, Belot, Alexandre, Ulloa-Gutiérrez, Rolando, Olbrich, Peter, Haerynck, Filomeen
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/166982
Acceso en línea:https://hdl.handle.net/11441/166982
https://doi.org/10.1016/j.jpeds.2022.05.028
Access Level:acceso abierto
Palabra clave:COVID-19
MIS-C
SARS-CoV-2
Adverse Events
Vaccination
Descripción
Sumario:The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after severe acute respiratory syndrome coronavirus 2 vaccination in 273 patients with a history of MIS-C.